JB Chemicals Posts Solid Operating Q3 Performance: ICICI Securities
A bottle of generic tablets produced by an Indian pharma firm. (Photographer: Dhiraj Singh/Bloomberg)

JB Chemicals Posts Solid Operating Q3 Performance: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

JB Chemicals and Pharmaceuticals Ltd.’s Q3 FY21 performance was strong at the operating level.

Revenue growth benefited by deferment of exports sales worth Rs 570 million from Q2 FY21 to Q3 FY21.

Consolidated revenue grew 27.9% YoY to Rs 5.5 billion while Ebitda margin improved 1030/640 basis points YoY/QoQ to 31.2% led by higher sales, operating leverage and continued cost benefits.

Adjusted profit after tax also grew strong 94.9% Rs 1.3 billion.

We remain positive considering approximately 45% of total revenues and ~60% of Ebitda contribution is from domestic formulations with strong growth visibility.

Click on the attachment to read the full report:

ICICI Securities JBCPL Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.